2023
Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia
Rodwin R, DelRocco N, Hibbitts E, Devidas M, Whitley M, Mohrmann C, Schore R, Raetz E, Winick N, Hunger S, Loh M, Hockenberry M, Ma X, Angiolillo A, Ness K, Kairalla J, Kadan‐Lottick N. Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer 2023, 70: e30634. PMID: 37592363, PMCID: PMC10552080, DOI: 10.1002/pbc.30634.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyLymphoblastic leukemiaPediatric Outcomes Data Collection InstrumentPT/OTSensory peripheral neuropathyAcute lymphoblastic leukemiaPredictor of motorProxy-report measuresCommon conditionOccupational therapistsNeuropathyChildrenLeukemiaFunction studiesResponse
2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkersPersistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal Of The National Cancer Institute 2022, 114: 1167-1175. PMID: 35552709, PMCID: PMC9360458, DOI: 10.1093/jnci/djac095.Peer-Reviewed Original ResearchBiomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Frontiers In Pain Research 2022, 3: 864910. PMID: 35360655, PMCID: PMC8963873, DOI: 10.3389/fpain.2022.864910.Peer-Reviewed Original ResearchPeripheral neuropathyChemotherapy-Induced Peripheral NeuropathyTreatment of CIPNMultiple chemotherapeutic agentsQuality of lifeImportant clinical toolCancer survivorsTherapeutic optionsCIPNClinical practicePreventative treatmentPromising biomarkerChemotherapeutic agentsClinical implicationsClinical toolCancer diagnosisBiomarkersNeuropathyStandardized objective measuresPatientsObjective measuresTreatmentRiskChemotherapyComplications
2021
Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic
Rodwin RL, Ross WL, Rotatori J, Allen K, Auerbach C, Balsamo LM, Kadan‐Lottick N. Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatric Blood & Cancer 2021, 69: e29550. PMID: 34971076, PMCID: PMC8805800, DOI: 10.1002/pbc.29550.Peer-Reviewed Original Research